

GLP Certificate holder

# MEDITOX

per aspera ad astra

[www.meditox.eu](http://www.meditox.eu)

**PRECLINICAL RESEARCH  
AND DEVELOPMENT**

**COMPREHENSIVE PRECLINICAL  
TOXICOLOGICAL PROGRAM**

**ANIMAL MODELS OF SELECTED  
HUMAN DISEASES**

**ACCREDITED BREEDING FACILITY  
FOR LABORATORY ANIMALS**



CARDIOLOGY DISEASES

HUNTINGTON'S DISEASE MODEL

DIABETES / OBESITY MODEL

OPHTHALMOLOGY DISEASES



## MediTox s.r.o.



**MediTox is a private independent CRO offering special tailored services with the emphasis on competitive price, flexibility, high quality and scientific standards.**

**Preclinical R&D**

**Comprehensive TOX/Safety program**

**Disease models**



- Argentina
- Australia
- Canada
- India
- Israel
- Singapore
- USA



Ireland

United Kingdom

Danmark  
Denmark

Nederland  
Netherlands

Belgie  
Belgique  
Belgium

Deutschland  
Germany

Polska  
Poland

Česká Rep  
Czech Rep

Slovensko  
Slovakia

Österreich  
Austria

France

Switzerland

Slovenia  
Hrvatska  
Croatia

Italia  
Italy

Portugal

España  
Spain

Ελλάς  
Greece

Srbija  
Serbia

Macedonia

Magyarország  
Hungary

România  
Romania

Bulgaria

Moldova

Україна  
Ukraine

Lietuva  
Lithuania

Latvija  
Latvia

Eesti  
Estonia

Suomi  
Finland

Sverige  
Sweden

Norge  
Norway

Беларусь  
Belarus

Kazakhstan

Georgia

Azerbaijan

Türkiye  
Turkey

Uzbekistan

Turkmenistan

Tajikistan



## **Good Laboratory Practice Certificate OECD GLP [C(97)186 Final]**

Next re-inspection: August 2022

## **Authorization to Use Experimental Animals**

Valid for: 2020 - 2025

## **Authorization to Breed Experimental Animals**

Valid for: 2020 - 2025

## **Authorization to Handle GMO**

in compliance with Act No. 153/2000 Coll.

## **Institution's Animal Welfare Assurance**

approved by **National Institute of Health, Office of Laboratory Animal Welfare (USA)**, Valid for: 2020 - 2025

## **Crédit Impôt Recherche (CIR) accreditation**

Valid for 2021 - 2023



## Experimental facilities available

**Conventional (rodents, non-rodents) & SPF housing (rodents)**

**Experimental facility for studies in cats**

**BSL II experimental facility for studies in rodents, rabbits and ferrets**

**Experimental facility for studies in mini pigs**

**Fully equipped surgical operating room for conducting studies requiring surgery**

**In-house clinical pathology & histopathology**

**Laboratory of in vitro methods**



## Test systems & administration routes available

### Non-rodent:

Dogs, rabbits, ferrets, cats, pigs/mini pigs, NHP

### Rodent:


Mice, rats, hamsters, guinea pigs

### In vitro:

Bacteria (S. tph, E. Coli), mammalian cells  
(human lymphocytes, erythrocytes, murine  
fibroblasts, etc.)

### Administration routes:

Buccal, cutaneous, intra-articular, intra-cardial,  
intra-dermal, intra-muscular, intra-nasal, intra-  
peritoneal, intra-vitreous, intra-venous, iocular,  
oral, rectal, sub-cutaneous, vaginal  
Implantation (bone, muscle, subcutis)



## Studies/tests available

### **Genetic toxicology**

EMA, ICH/VICH, OECD TG, ISO 10993

### **General toxicology/non-clinical safety**

EMA, ICH/VICH, OECD TG

### **Safety pharmacology**

EMA, ICH/VICH

### **PK, TK, BEQ, BA**

OECD TG, ICH/VICH

### **Local effects**

EMA, ICH, ISO 10993

### **Medical device bio-compatibility**

ISO 10993

### **Veterinary drugs assessment**

VICH GL



## Disease models

### Available models:

Chronic glaucoma, dog

Acute contact dermatitis, pig/mini pig


Human influenza, ferret

Osteoarthritis (CLT), dog


### Models under development

Chronic glaucoma, rabbit

Osteoarthritis, rabbit







## Participation in R&D projects

### **FLUVAC: Live attenuated replication-defective influenza vaccine**

Austria (AGBT), Germany, Russia, Slovenia, Czech Republic

### **ANTIFLU: Innovative anti-influenza drugs excluding viral escape**

Denmark, France, Germany (MPI), Hungary, Israel, United Kingdom, Czech Republic

### **OSTEOGROW: Novel morphogenetic protein-6 biocompatible carrier device**


Austria, Bosnia and Herzegovina, Croatia (UZ), Czech Republic, Sweden

### **MOTIF: Microbicide optimization through innovative formulation for vaginal and rectal delivery**

Czech Republic, France, Italy, United Kingdom (KCL)

## A bit of statistics...


Structure of experimental work



- GLP, regulatory, 65 %
- Non-GLP, preparatory, 35 %
- Contracted-based, 75 %
- Scientific coop., 25 %


## A bit of statistics...

Regional structure of clients




## A bit of statistics...

Branch structure of clients



- Pharma/Biotech companies
- Medical device
- Academia/University
- Chem/agrochem industry





## Selection of references

**Alzprotect**, France

**Amega Biotech**, Argentina

**Bioceltix**, Poland

**California Univ**, USA

**Celon Pharma**, Poland

**CONTIPRO a.s.**, CR

**CR. HANSEN**, Denmark

**Cromepharma**, UK

**Dicot**, Sweden

**EirGen Pharma**, Ireland

**Faraday, Inc.**, USA

**FATRO**, Italy

**Gelesis Inc**, USA

**HUVE Pharma**, Bulgaria/Belgium

**INEB**, Portugal

**Klifovet**, Germany

**KANCERA**, Sweden

**KRKA**, Slovenia

**Lesaffre**, France

**Lupin Pharma**, India

**Mabion**, Poland

**Mount Sinai School of Medicine**, USA

**Nicox**, Italy

**NovoNordisk**, Denmark

**Olainfarm**, Latvia

**Regivet**, The Netherlands

**Rottapharm**, Italy

**Sanofi Group (Zentiva)**

**Sunpharma**, India

**Triveritas**, UK

**Univ of Medicine and Health Sciences**,  
Ireland

**Vetcare Oy**, Finland

**Virbac**, France



# MEDITOX

per aspera ad astra





# MEDITox

per aspera ad astra





# MEDITOX

per aspera ad astra





# MEDITox

per aspera ad astra





# MEDITOX

per aspera ad astra

